The company offers testing services to physicians and individuals, researchers and corporations across many industries and regions, developing the adoption of telomeres and telomerase activity as key health biomarkers, advancing towards better and longer lifespans. They also use its patented technology in in vitro and clinical animal studies in the areas of nutraceuticals, biotech/pharma, infertility, veterinary and cosmetics among others for clinics, companies, researcher groups, hospitals among others.
One of its main areas of service is oncology, in which it is well advanced in offering minimally invasive blood tests for the early diagnosis of various types of cancer through the measurement of telomeres and its associated variables.
Additionally, in an impressively short of time, in March 2020, the company started to perform RT-PCR, Quick Antigens Tests, Quick Antibodies Tests, ELISA Tests and COVID Cellular Immunity Tests and has served over 400,000 clients, opening a new clinic in Madrid and becoming Spain’s mostly highly rated laboratory.
The company is now preparing to expand the business and will soon offer new tests at its clinic. These multiple tests, related to personalized and preventive medicine, will be accompanied by a medical, nutritional and/or genetic consultation.
Since 2016, the company is also Spain’s most accredited laboratory; the only U.S. Federal laboratory under Clinical Laboratory Improvement Amendments (CLIA-88) and International Organization for Standardization (ISO 15189) were completed in and all the critical aspects of the test are controlled and supervised accordingly. Moreover, its laboratories had in situ reviews annually by regulators from 2017 to 2021 with reaccreditation and satisfactory results.
The company has applied for patents and is expecting to have CE (European Conformity) marking and the International Organization for Standardization (ISO-13485) certification. In 2021, Life Length has also received the accreditation C.2.5.6 as a Diagnostic Centre with units of U.72 Obtaining Samples, U.73 Clinical Analysis and U.74 Clinical Biochemistry from the Regional Government of Madrid, Spain.
The company is expecting accreditation from the European Medicines Agency (EMA) for the use of its test in prostate cancer screening in 2022 and approval in the U.S. through the Food and Drug Administration (FDA) as an In Vitro Diagnostic (IVD), with similar pathway for lung cancer screening to commence in the near future.
The company is seeking partners in the field of diagnostic oncology for prostate and lung cancer companies from the pharma, biotech /life sciences and nutraceutical companies -for in vitro and in vivo testing and studies- as well as personalized and preventive medicine companies.
The types of partnerships considered are financial agreements, joint venture agreements and commercial agency agreements.